Equities

Oncolytics Biotech Inc

ONCY:NAQ

Oncolytics Biotech Inc

Actions
  • Price (USD)0.9541
  • Today's Change-0.026 / -2.64%
  • Shares traded350.87k
  • 1 Year change-40.37%
  • Beta1.6687
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-27.64m
  • Incorporated1998
  • Employees29.00
  • Location
    Oncolytics Biotech Inc1167 Kensington Cres Nw Suite 210Calgary Alberta Canada T2n 1X7CALGARY T2R 0C5CanadaCAN
  • Phone+1 (403) 670-7377
  • Fax+1 (403) 283-0858
  • Websitehttps://www.oncolyticsbiotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vistagen Therapeutics Inc875.70k-39.57m70.44m45.00--0.7362--80.44-1.30-1.300.02893.440.0121----22,453.85-54.69-62.84-58.94-68.03-----4,518.12-5,768.52----0.00--568.10--50.44---18.91--
Aligos Therapeutics Inc6.00m-76.95m71.00m68.00--1.36--11.84-18.70-18.701.1214.530.0688----90,863.63-88.31-51.20-117.62-59.73-----1,283.19-1,399.21----0.004--11.66--8.71---62.36--
Regencell Bioscience Holdings Ltd0.00-4.30m73.52m12.00--8.95-----0.3306-0.33060.000.63160.00----0.00-41.44-56.31-42.99-77.51------------0.00------26.73------
VolitionRX Ltd1.29m-29.87m74.69m110.00------58.09-0.3623-0.36230.0155-0.23280.0837--7.4111,689.36-196.61-111.92---196.20-----2,348.71-10,793.31---104.15----153.04---16.68--29.13--
Ovid Therapeutics Inc631.56k-32.50m75.23m25.00--0.9866--119.12-0.4598-0.45980.00891.070.0056----15,789.00-28.55-20.78-31.34-23.27-----5,146.15-56.16----0.00---73.93--3.38---17.14--
Adicet Bio Inc0.00-117.88m75.31m143.00--0.356-----1.70-1.700.002.570.00----0.00-49.20-37.03-53.58-40.28-------748.46----0.00---100.00---104.41--65.27--
Aerovate Therapeutics Inc0.00-84.61m75.34m51.00--0.936-----2.99-2.990.002.790.00----0.00-72.99---81.83--------------0.00-------46.61------
Oncolytics Biotech Inc (USA)0.00-19.79m75.55m29.00--11.65-----0.2608-0.26080.000.08410.00-------78.58-81.99-104.96-97.25------------0.1051-------11.75---40.52--
Armata Pharmaceuticals Inc5.47m-41.36m75.98m66.00------13.90-1.24-1.240.1312-1.410.0518--1.0282,833.34-39.21-59.78-116.66-72.70-----756.59-1,113.72----1.90---17.77---87.03--184.10--
P3 Health Partners Inc1.48bn-102.69m76.91m400.00--0.289--0.0521-0.753-0.75311.080.7441.71--12.283,691,575.00-28.94---83.29---2.720.1781-16.95-56.93---12.940.3358--20.6770.5878.61---11.20--
Clearside Biomedical Inc7.70m-31.88m77.36m30.00------10.04-0.4503-0.45030.1094-0.46540.2423--9.23256,766.70-100.27-63.57-122.24-81.7797.01---413.83-231.80--------519.89207.341.40--82.41--
ESSA Pharma Inc0.00-27.67m78.12m50.00--0.606-----0.6257-0.62570.002.900.00----0.00-19.33-23.01-19.81-23.67------------0.00------24.27------
Sellas Life Sciences Group Inc0.00-32.28m78.49m16.00--4.94-----0.7113-0.71130.000.24680.00----0.00-186.64-111.48-527.32-184.29-------1,289.42----0.00---100.00--9.59------
CervoMed Inc10.07m-11.95m79.07m8.00--1.73--7.85-1.60-1.601.355.530.3305----1,258,319.00-39.22-53.67-43.28-58.89-----118.68-949.54----0.00------86.07------
Werewolf Therapeutics Inc3.39m-62.12m79.32m45.00--0.8707--23.43-1.50-1.500.08192.040.0214--1.0672,042.55-39.26---42.91-------1,834.55------0.2228--21.60--30.56------
Renovaro Inc0.00-115.69m79.49m25.00--0.8047-----0.9343-0.93430.000.62230.00----0.00-128.97-39.86-158.19-42.11-----------9.650.0259-------103.23---37.12--
Data as of Nov 22 2024. Currency figures normalised to Oncolytics Biotech Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.